Market News
Stay updated with the latest market trends, earnings, and economic indicators.
GenXAI Analytics shares set for listing. Here's what GMP suggests ahead of debut
GenXAI Analytics is set for its NSE SME debut with a subdued grey market premium, indicating a likely listing price near its issue price. The company's Rs 54.8 crore IPO, fully subscribed, aims to fund product development and working capital. GenXAI offers AI-driven enterprise performance and analytics solutions across various sectors.
Hexagon Nutrition IPO listing date today. GMP, analysts signal share debut at a minor premium on BSE, NSE - Mint
Hexagon Nutrition IPO listing date today. GMP, analysts signal share debut at a minor premium on BSE, NSEMint
Vahh Chemicals share price lists at 17% premium over IPO price on BSE SME
Vahh Chemicals share price listed at ₹70 apiece as against the initial public offering (IPO) price of ₹60, a premium of 16.66%. The stock rose marginally to its day's high of ₹71 but then reversed trend to hit the 5% lower price band of ₹66.50 apiece.
Analyst suggests buying Nestle India, Bharat Forge today: Check targets
Stocks to buy: Ruchit Jain of Motilal Oswal Financial Services has recommended buying the shares of Nestle India, and Bharat Forge today
Nifty 500 Q4 Review: HDFC Bank, Indian Oil, Tata Motors Among Top Winners, Losers; Key Sector Trend — Read Motilal Oswal's Report
Of the 23 key sectors, 14 posted double-digit profit growth in Q4 FY26.
CMR Green Technologies share price makes a bumper debut, opens with 40% premium at ₹268 apiece on NSE
CMR Green Technologies shares debuted strongly on 10 June, opening 39.58% higher on NSE and 43.44% on BSE. The IPO was subscribed to 127 times, reflecting robust investor interest, particularly from QIBs and NIIs, despite broader market volatility.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
Motilal Oswal 'bull case' sees 71% upside in this auto parts manufacturer
Motilal Oswal said Gabriel India is undergoing a structural transformation from a single-product suspension manufacturer into a diversified mobility platform, opening up a significantly larger growth runway, and it believes it is increasingly being positioned as the primary growth vehicle of the Anand Group.
Gabriel India shares rise 4%; Motilal Oswal initiates coverage with 'Buy'
Motilal Oswal Financial Services initiated coverage on the stock with a 'Buy' rating and a target price of ₹1,266
Gabriel India Shares in Focus After Motilal Oswal Initiates Coverage with 'Buy' — Check Target Price, Potential Upside
Consistent dividend payouts reflects Gabriel India's ability to generate and return surplus cash to shareholders across business cycles.